Summary
KKR & Co. Inc. (KKR) has filed an 8-K report detailing a key change in its Board of Directors. On June 15, 2022, Raymond J. McGuire was appointed to the Board. Mr. McGuire's compensation as a non-executive director includes a prorated annual cash retainer of $110,000 and a prorated equity grant of 1,202 restricted stock units vesting on October 1, 2022. This appointment, along with an increase in the Board size to seventeen members, was approved by the sole holder of KKR's Series I preferred stock.
Key Highlights
- 1Raymond J. McGuire appointed to the KKR Board of Directors effective June 15, 2022.
- 2Board size increased to seventeen directors.
- 3Mr. McGuire to receive a prorated annual cash retainer of $110,000.
- 4Mr. McGuire granted 1,202 restricted stock units, vesting on October 1, 2022.
- 5Dane Holmes appointed to the Audit Committee, increasing its size to four members.
- 6The appointment of Mr. McGuire and the Board expansion were approved by written consent of the Series I preferred stockholder.
Frequently Asked Questions
Raymond J. McGuire has been appointed to the Board of Directors of KKR. While the filing does not detail his background, appointments to a public company's board typically bring valuable experience and perspective, which can be of interest to investors assessing the company's governance and strategic direction.
As a non-executive director, Mr. McGuire will receive a prorated annual cash retainer of $110,000 and a prorated annual equity grant of 1,202 restricted stock units. The equity award is scheduled to vest on October 1, 2022. He also entered into KKR's standard indemnification agreement for directors.
The Board of Directors was increased to seventeen members to accommodate the appointment of Mr. McGuire. This decision was formally approved by KKR Management LLP, acting as the sole holder of the Series I preferred stock.
The size of the Audit Committee was increased to four members, and Dane Holmes, an existing director, was appointed to serve on it. This expansion and appointment are effective as of June 15, 2022.